Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786814 | 1.00 | NR1H4 (0.52) | NR1H4TTRAPPCA12CA1 | |
| SCHEMBL6030025 | 1.00 | NR1H4 (0.52) | NR1H4TTRAPPCA12CA1 | |
| SCHEMBL6821846 | 0.91 | NR1H4 (0.46) | NR1H4TTRAPPCA12CA1 | |
| SCHEMBL6821849 | 0.91 | NR1H4 (0.46) | NR1H4TTRAPPCA12CA1 | |
| SCHEMBL12677375 | 0.84 | MAOB (0.64) | NR1H4ALDH1A1GAAMAPTLMNA | |
| SCHEMBL12498146 | 0.83 | APP (0.60) | NR1H4TTRAPPCA12CA1 | |
| SCHEMBL1797240 | 0.83 | CYP1A2 (0.66) | TTRAPPCA12CA1CA2 | |
| SCHEMBL1797241 | 0.83 | CYP1A2 (0.66) | TTRAPPCA12CA1CA2 | |
| SCHEMBL5779119 | 0.82 | CES2 (0.44) | NR1H4ALDH1A1GAAMAPTLMNA | |
| SCHEMBL531541 | 0.82 | CYP3A4 (0.55) | TTRCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-7102046-B2 | By reaction of haloaromatics or arylsulfonates with olefins in presence of palladium catalyst, bulky nitrogen base and salt | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20030105353-A1 | Process for the arylation of olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | NR1H4 175/4885TTR 3750/4885APP 3196/4885 |
| US-20030105353-A1 | Process for the arylation of olefins | NEK6, JUN, AOC2 | NR1H4 1000/4885TTR 4144/4885APP 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.